Elexacaftor–tezacaftor–ivacaftor: The new paradigm to treat people with cystic fibrosis with at least one p.Phe508del mutation
Author:
Publisher
Elsevier BV
Subject
Drug Discovery,Pharmacology
Reference21 articles.
1. The future of cystic fibrosis care: a global perspective;Bell;Lancet Respir Med,2020
2. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA;Riordan;Science,1989
3. Sodium channels and cystic fibrosis;Donaldson;Chest,2007
4. https://cftr2.org.
5. Cystic fibrosis;Rowe;N Engl J Med,2005
Cited by 16 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Relationship Between Lung Volumes and Heterogeneity in the Response to Elexacaftor/Tezacaftor/Ivacaftor in Patients With Cystic Fibrosis and Advanced Lung Disease;CHEST;2024-09
2. Evaluation of elexacaftor–tezacaftor–ivacaftor treatment in individuals with cystic fibrosis and CFTRN1303K in the USA: a prospective, multicentre, open-label, single-arm trial;The Lancet Respiratory Medicine;2024-08
3. The network of cardiac KIR2.1: its function, cellular regulation, electrical signaling, diseases and new drug avenues;Naunyn-Schmiedeberg's Archives of Pharmacology;2024-04-29
4. Comprehensive Characterization of LAT1 Cholesterol-Binding Sites;Journal of Chemical Theory and Computation;2024-04-10
5. Elexacaftor–tezacaftor–ivacaftor for cystic fibrosis with Phe508del mutation: Evidence from randomized controlled trials;SAGE Open Medicine;2024-01
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3